The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Menthol cigarette alternatives pose significant addiction and health risks

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

In April 2022, FDA issued proposed product standards banning menthol flavoring in cigarettes and cigars; however, the benefits of these product standards could be weakened by the role of substitute products still available in the market.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Lifileucel shrinks tumors in mNSCLC in phase II trial

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute said results of a phase II, multi-center clinical trial revealed that a new type of cell therapy is a promising potential treatment option for patients with stage 4 lung cancer who were previously treated but later developed resistance to other therapies.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account